To validate that the more aggressive tumor growth of sMICB-expressing tumors in current experimental settings is associated with impairment of NK and CD8 T cell immunity, we assayed the function of tumor-infiltrated NK and CD8 T cells (Supplement Figure S2), both of which express the receptor NKG2D for sMICB and are critical anti-tumor effector cells. This evidence concerns the gene KLRK1 and neoplasm.